Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lessened its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,756 shares of the biopharmaceutical company’s stock after selling 1,098 shares during the quarter. The Manufacturers Life Insurance Company owned 0.05% of Dynavax Technologies worth $744,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares during the last quarter. US Bancorp DE grew its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $45,000. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares in the last quarter. Finally, Algert Global LLC bought a new position in shares of Dynavax Technologies during the second quarter worth about $140,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Down 0.2 %

DVAX stock opened at $12.96 on Friday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 99.70 and a beta of 1.33. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The firm has a fifty day moving average price of $11.98 and a two-hundred day moving average price of $11.47. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.